Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare genetic disorder with an autosomal recessive pattern of inheritance. It is caused by the ineffective or decreased biosynthesis of the fifth complement component, C5. C5 deficiency may also be acquired acutely post-infection. If C5 is adequately synthesized, its rapid depletion may result in a functional deficiency. Clinical signs of the inherited deficiency present within the second decade of life and are consistent with the signs of recurrent systemic infection. Deficiency of serum C5 and its major cleavage product, C5b, a component of the membrane attack complex, increases susceptibility to Neisserial infections.
Features include always present findings: Reduced circulating CH50 activity, Recurrent meningococcal disease, and Decreased circulating complement C5 concentration. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 1 | Intractable diarrhea |
C5 encodes complement C5 (1,676 aa). Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. Highest expression in Liver (121.1 TPM) and Nerve Tibial (15.4 TPM).
Complement component 5 deficiency is associated with mutations in the C5 gene on chromosome 9.
The C5 protein participates in C5:C5 inhibitors pathway.
C5 is classified as a druggable target (Druggable Genome, Enzyme, and Protease Inhibitor categories) with score 3.3.
Genetic testing for C5 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for complement component 5 deficiency has been reported in the published literature.
Phenotype severity distribution: 3 always present features.
No clinical trials have been registered for complement component 5 deficiency.
61 publications have been identified in PubMed for complement component 5 deficiency. Research spans Basic Science / Preclinical (57%), Review / Meta-Analysis (20%), and Clinical Trial Publication (10%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 35 | 57% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 8:40 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about complement component 5 deficiency
1 |
Recurrent Neisserial infections |
Skin | 1 | Generalized seborrheic dermatitis |
Research summaries
12 |
20% |
Clinical study results | 6 | 10% |
Patient case studies | 5 | 8% |
Testing and diagnosis research | 1 | 2% |
Disease patterns and progression | 1 | 2% |
New treatment approaches | 1 | 2% |
Dawoodbhoy KM (2026). [PMID: 42113875](https://pubmed.ncbi.nlm.nih.gov/42113875/). *PLoS Pathog*. [Basic Science / Preclinical]
Tahiat A (2026). [PMID: 42205540](https://pubmed.ncbi.nlm.nih.gov/42205540/). *J Hum Immun*. [Clinical Trial Publication]
Mallett G (2026). [PMID: 42131334](https://pubmed.ncbi.nlm.nih.gov/42131334/). *Front Immunol*. [Basic Science / Preclinical]
Justiz Vaillant AA (2026). [PMID: 29763203](https://pubmed.ncbi.nlm.nih.gov/29763203/). *Unknown Journal*. [Review / Meta-Analysis]
Ozturk NK (2026). [PMID: 41873719](https://pubmed.ncbi.nlm.nih.gov/41873719/). *Immunotherapy*. [Review / Meta-Analysis]
Lu X (2026). [PMID: 41177456](https://pubmed.ncbi.nlm.nih.gov/41177456/). *Journal of thrombosis and haemostasis : JTH*. [Basic Science / Preclinical]
Jiang Y (2026). [PMID: 41793014](https://pubmed.ncbi.nlm.nih.gov/41793014/). *Nephrology (Carlton, Vic.)*. [Case Report / Case Series]
Rutt LN (2026). [PMID: 42217620](https://pubmed.ncbi.nlm.nih.gov/42217620/). *Am J Pathol*. [Basic Science / Preclinical]
Zhang Z (2026). [PMID: 41237697](https://pubmed.ncbi.nlm.nih.gov/41237697/). *International immunopharmacology*. [Basic Science / Preclinical]
Kang S (2026). [PMID: 41529218](https://pubmed.ncbi.nlm.nih.gov/41529218/). *Neurology(R) neuroimmunology & neuroinflammation*. [Case Report / Case Series]